Activating lipid nanoparticles can streamline... - CLL Support

CLL Support

23,257 members39,957 posts

Activating lipid nanoparticles can streamline the production of CAR T-cells for cancer immunotherapy

bennevisplace profile image
3 Replies

A bio- engineering breakthrough is reported here phys.org/news/2024-03-metho... and the article includes a link to the open access research paper.

Sorry, that's all folks. This is a phone and I'm on holiday. Italy shouldn't be this wet.

Ciao.

Written by
bennevisplace profile image
bennevisplace
To view profiles and participate in discussions please or .
Read more about...
3 Replies
AussieNeil profile image
AussieNeilPartnerAdministrator

That's a very interesting paper, thanks Bennevisplace - a silver lining for us from your poor holiday weather, which I hope improves for you. It explains a breakthrough which reduces the time to make CAR-T cells, by using the same technology used in the very successful mRNA based COVID-19 vaccines - activating lipid nanoparticles.

From the article introduction;

For patients with certain types of cancer, CAR T cell therapy has been nothing short of life changing. Developed in part by Carl June, Richard W. Vague Professor at the Perelman School of Medicine, and approved by the Food and Drug Administration (FDA) in 2017, CAR T cell therapy mobilizes patients' own immune systems to fight lymphoma and leukemia, among other cancers.

However, the process for manufacturing CAR T cells themselves is time-consuming and costly, requiring multiple steps across days. The process involves extracting patients' T cells, then activating them with tiny magnetic beads, before giving the T cells genetic instructions to make chimeric antigen receptors (CARs), the specialized receptors that help T cells eliminate cancer cells.

Now, Penn Engineers have developed a novel method for manufacturing CAR T cells, one that takes just 24 hours and requires only one step, thanks to the use of lipid nanoparticles (LNPs), the potent delivery vehicles that played a critical role in the Moderna and Pfizer-BioNTech COVID-19 vaccines.

In a new paper published in Advanced Materials, Michael J. Mitchell, associate professor in bioengineering, describes the creation of "activating lipid nanoparticles" (aLNPs), which can activate T cells and deliver the genetic instructions for CARs in a single step, greatly simplifying the CAR T cell manufacturing process.

Of note, both Pfizer-BioNTech and Moderna were working on cancer applications of their mRNA delivery process before a pandemic resulted in a temporary redirection of their efforts :(

From Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

thelancet.com/journals/lano...

In 1996, the first mRNA-based cancer vaccine study tested dendritic cells pulsed with RNA in vitro.8

Nowadays, technological advances have led to optimised mRNA structure, stability, and delivery methods, and multiple clinical trials are now enrolling patients with cancer for mRNA-based vaccine treatments.

And from the USA's National Cancer Institute Can mRNA Vaccines Help Treat Cancer?

cancer.gov/news-events/canc...

The coronavirus pandemic has thrown a spotlight on messenger RNA (mRNA)—the molecule that carries a cell’s instructions for making proteins. Hundreds of millions of people worldwide have received mRNA vaccines that provide powerful protection against severe COVID-19 caused by infection with SARS-CoV-2.

As stunningly successful as the mRNA COVID-19 vaccines have been, researchers have long hoped to use mRNA vaccines for a very different purpose—to treat cancer. mRNA-based cancer treatment vaccines have been tested in small trials for nearly a decade, with some promising early results.

In fact, scientists at both Pfizer-BioNTech and Moderna drew on their experience developing mRNA cancer vaccines to create their coronavirus vaccines.

Exciting times!

Neil

Activating lipid nanoparticles (as used in mRNA vaccines), simplify CAR-T manufacture
bennevisplace profile image
bennevisplace in reply toAussieNeil

Thanks for setting out the highlights Neil. Couldn't have done it better myself 😅

LeoPa profile image
LeoPa

Now that's promising!

Not what you're looking for?

You may also like...

Immunotherapy and Gene Modification of T Cells

I'm diagnosed as of April 2018, and like so many others in the Watch and Wait phase. I hate this...
wizzard166 profile image

The health of our T cells…

I am wondering if the health of T cells in CLL generally declines if there is disease progression....
Luap001 profile image

Tuesday! Nov. 17th CLL Society Webinar "The Future of CAR-T Therapy: Can CAR-T Cure CLL?”

Tuesday! Nov. 17th CLL Society Webinar "The Future of CAR-T Therapy: Can CAR-T Cure CLL?” Claim...
bkoffman profile image
CLL CURE Hero

The current status and challenges of CAR-T therapy in CLL

A few members of this group are scheduled for CAR-T and others might find themselves in the same...
Jm954 profile image
Administrator

EHA 2019: Dr. Maloney on CAR-T and Dr. Davids of Chemo-Immunotherapy combinations

David Maloney is world expert in CAR-T therapy and was one of my doctors when I got my genetically...
bkoffman profile image
CLL CURE Hero